A new personalized cancer vaccine has shown encouraging results in preventing the return of kidney cancer after surgery. Researchers at Dana-Farber Cancer Institute tested the vaccine in nine patients with stage III or IV clear cell renal cell carcinoma (a form of kidney cancer).
All patients remained cancer-free at a median follow-up of nearly three years. The study, published in Nature, highlights a potential breakthrough in cancer treatment.
How the Vaccine Works
The vaccine is designed to train the immune system to recognize and destroy any remaining cancer cells after surgery. It is created specifically for each patient using tumor tissue removed during surgery.
Scientists analyze the tumor to find neoantigens—mutated proteins unique to the cancer cells. These neoantigens help the immune system target cancer without attacking healthy tissue.
Using predictive algorithms, researchers select the most effective neoantigens for each patient’s vaccine. The vaccine is then given through a series of initial doses, followed by booster shots to strengthen the immune response.
Promising Early Results
All nine patients in the Phase I clinical trial developed a strong immune response after receiving the vaccine. Their immune systems produced T cells—specialized white blood cells that attack cancer—which remained in their bodies for up to three years.
On average, the number of these vaccine-induced T cells increased by 166-fold, showing that the immune system was effectively trained to fight cancer. In laboratory tests, these T cells successfully attacked the patients’ own tumor cells, confirming that they were still active long after vaccination.
The Need for New Treatments
Currently, the standard treatment for advanced kidney cancer is surgery, followed by immunotherapy with pembrolizumab(an immune checkpoint inhibitor). However, even with this treatment, about two-thirds of patients experience a cancer recurrence and have limited options if the disease returns.
“Patients with stage III or IV kidney cancer are at high risk of recurrence,” said Dr. Toni Choueiri, co-lead investigator of the study. “The tools we have to lower that risk are not perfect, and we are relentlessly looking for more.”
Safety and Side Effects
The vaccine was well tolerated. Some patients experienced mild side effects, such as flu-like symptoms or reactions at the injection site, but no serious complications were reported. This suggests that the vaccine provides a targeted immune response without triggering harmful effects on healthy tissues.
A Step Forward in Cancer Vaccination
The concept of personalized cancer vaccines is not entirely new. Similar vaccines have shown promise in melanoma, a skin cancer with many mutations that provide multiple targets for immune attack. However, kidney cancer has fewer mutations, making it harder to develop an effective vaccine.
Despite this challenge, the study demonstrated that a personalized vaccine can still generate a strong and lasting immune response in kidney cancer patients.
“This approach is truly distinct from past cancer vaccines,” said Dr. David Braun, co-senior author of the study. “We specifically pick targets that are unique to the cancer, making the immune system attack the tumor with high precision.”
Next Steps: Larger Clinical Trials
While the results are promising, larger studies are needed to confirm the vaccine’s effectiveness. A new international clinical trial (NCT06307431) is already underway to test a similar neoantigen vaccine in combination with pembrolizumab in more patients.
“Our results support the feasibility of a personalized cancer vaccine in a cancer with a lower mutation burden,” said Dr. Patrick Ott, co-author of the study. “These findings are encouraging, but we need larger trials to fully understand the clinical impact.”
If future studies confirm these early findings, personalized cancer vaccines could become a powerful tool in preventing cancer recurrence and improving long-term survival.
If you care about cancer, please read studies that low-carb diet could increase overall cancer risk, and new way to increase the longevity of cancer survivors.
For more information about cancer, please see recent studies about how to fight cancer with these anti-cancer superfoods, and results showing daily vitamin D3 supplementation may reduce cancer death risk.
The research findings can be found in Nature.
Copyright © 2025 Knowridge Science Report. All rights reserved.
